MELVILLE, N.Y.--(BUSINESS WIRE)--OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) and Roche, its international partner for Tarceva® (erlotinib), announced today that the European Commission has granted marketing authorization for Tarceva in combination with gemcitabine as first-line therapy for metastatic pancreatic cancer. The Tarceva-gemcitabine combination is the only new treatment regimen in a decade to show, in a Phase III clinical trial, a statistically significant improvement in overall survival compared with gemcitabine alone, when administered as initial therapy to patients with advanced stages of pancreatic cancer.
